pharma · Chronic Lymphocytic Leukemia (CLL) · Chronic Lymphocytic Leukemia · APVO
Aptevo Therapeutics
Aptevo Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Seattle, USA
- Founded
- 2016
- Employees
- 54
- Programs
- 9
- Drugs
- 4
- Patents
- 13
Aptevo Therapeutics projects
9 ClinicalTrials.gov programs sponsored by Aptevo Therapeutics.
Aptevo Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ALG.APV-527
Aptevo Therapeutics
Solid Tumor
1 trial -
TRU-016 and bendamustine
Aptevo Therapeutics
Chronic Lymphocytic Leukemia (CLL)
1 trial -
20 mg/kg TRU-016 + Rituximab
Aptevo Therapeutics
Chronic Lymphocytic Leukemia
1 trial -
APVO210
Aptevo Therapeutics
Psoriasis
1 trial -
APVO436
Aptevo Therapeutics
AML
2 trials -
APVO436
Aptevo Therapeutics
Acute Myeloid Leukemia (AML)
1 trial -
ES414
Aptevo Therapeutics
Prostate Cancer
1 trial -
TRU-016
Aptevo Therapeutics
B-cell Small Lymphocytic Lymphoma Recurrent
1 trial -
TRU-016 (anti-CD37 protein therapeutic)
Aptevo Therapeutics
Chronic Lymphocytic Leukemia (CLL)
1 trial
Frequently asked questions
How many clinical projects does Aptevo Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.